SFRP2 and Myocardial fibrosis: Since they only enrolled patients with severe decompensated HF and NYHA functional class III–IV, the disparity may be attributed to different stages of HF and the elevated sFRP2 in their study may be a compensatory factor to counteract myocardial fibrosis.